<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d134" origId="Botulinum Toxin Type A"><sentence id="DrugDDI.d134.s0" origId="s0" text="Co-administration of BOTOX? and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated."><entity id="DrugDDI.d134.s0.e0" origId="s0.p3" charOffset="32-47" type="drug" text="aminoglycosides"/><entity id="DrugDDI.d134.s0.e1" origId="s0.p10" charOffset="115-121" type="drug" text="curare"/><entity id="DrugDDI.d134.s0.e2" origId="s0.p19" charOffset="197-202" type="drug" text="toxin"/><pair id="DrugDDI.d134.s0.p0" e1="DrugDDI.d134.s0.e0" e2="DrugDDI.d134.s0.e1" interaction="?"/><pair id="DrugDDI.d134.s0.p1" e1="DrugDDI.d134.s0.e0" e2="DrugDDI.d134.s0.e2" interaction="?"/><pair id="DrugDDI.d134.s0.p2" e1="DrugDDI.d134.s0.e1" e2="DrugDDI.d134.s0.e2" interaction="?"/></sentence><sentence id="DrugDDI.d134.s1" origId="s1" text="The effect of administering different botulinum neurotoxin serotypes at the same time or within several months of each other is unknown."><entity id="DrugDDI.d134.s1.e0" origId="s1.p24" charOffset="38-58" type="drug" text="botulinum neurotoxin"/></sentence><sentence id="DrugDDI.d134.s2" origId="s2" text="Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin."><entity id="DrugDDI.d134.s2.e0" origId="s2.p36" charOffset="81-97" type="drug" text="botulinum toxin"/><entity id="DrugDDI.d134.s2.e1" origId="s2.p39" charOffset="165-181" type="drug" text="botulinum toxin"/><pair id="DrugDDI.d134.s2.p0" e1="DrugDDI.d134.s2.e0" e2="DrugDDI.d134.s2.e1" interaction="?"/></sentence></document>